Turbo
My main aim was to quash any notion that the diverging facts presented in this report were the result of the analyst having been given special inside information by Jon Pilcher.
Proper biotech analysis, I suspect, is particularly demanding and requires a wide range of very high level skills. Then there’s the matter that financial incentive is lacking in Australia.
To be fair, not all biotech analysis in Australia is worthless. There are a number of capable biotech analysts in Australia who deserve credit for what they do.
Neuren Media and Analyst Coverage, page-1133
-
- There are more pages in this discussion • 110 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add NEU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$20.52 |
Change
0.660(3.32%) |
Mkt cap ! $2.622B | |||
| Open | High | Low | Value | Volume |
| $20.00 | $20.66 | $19.94 | $6.431M | 315.4K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 1024 | $20.52 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $20.53 | 285 | 1 |
View Market Depth
| Last trade - 16.10pm 12/07/2024 (20 minute delay) ? |
| NEU (ASX) Chart |